Compare Ascendis Pharma A/S (ASND) vs Rockwell Automation (ROK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Rockwell Automation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Rockwell Automation trades at $470.46 (market cap $52.53B). The key difference: Rockwell Automation is far larger — about 3× Ascendis Pharma A/S's market cap, and Rockwell Automation pays a 1.17% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | ROK | |
|---|---|---|
Market Cap | $17.74B | $52.53B |
Sector | Health | Industrials |
52-Week High | $277.18 | $495.08 |
52-Week Low | $163.32 | $328.67 |
Enterprise Value | $18.11B | $56.17B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Rockwell Automation (ROK) trades at $472.12, up 0.99% on the day, showing strong momentum with three consecutive earnings beats. The stock's technical picture is neutral with bullish moving averages, while valuation multiples remain elevated with a P/E of 49.03. Recent news highlights the company's leadership in industrial automation and AI infrastructure growth potential, with multiple Zacks recognition as a top momentum and growth stock in July 2026.
ROK presents a mixed outlook with strong operational cash flow and recent earnings outperformance offset by premium valuations. Investment opportunity lies in industrial automation growth and AI infrastructure tailwinds, while risks include competitive pressures and sensitivity to industrial spending cycles. Analyst consensus leans cautious with 64% hold ratings despite recent positive coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
